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GoatAbstract The pharmacokinetic profile of cefoperazone was studied in goats following intravenous
and intramuscular administration of 20 mg/kg body weight. Cefoperazone concentrations in serum
were determined by microbiological assay technique using Escherichia coli (ATCC 10536) as test
organism. Following i.v. administration, the cefoperazone serum concentration–time curve was best
fitted in a two compartment open model. Cefoperazone has moderate distribution in the body of
goats with Vdss of 0.44 ± 0.03 L/kg. The elimination half-life (T0.5(b)), area under curve (AUC)
and total body clearance (Cltot) were 1.97 ± 0.14 h, 149.63 ± 8.61 lg ml
1 h1, and 2.17 ml/min/
kg, respectively. Following i.m. administration, the drug was very rapidly absorbed, with an absorp-
tion half-life (T0.5(ab)) of 0.12 ± 0.01 h. The maximum serum concentration (Cmax) of 30.42 ± 3.53
lg ml1 was attained at (Tmax) 0.58 ± 0.02 h, with an elimination half-life (T0.5(el)) of 2.53
± 0.11 h. The systemic bioavailability of cefoperazone in the goats after i.m. administration was
83.62% and in vitro protein binding was 20.34%. The serum concentrations of cefoperazone along
12 h post i.m. injection in this study were exceeding the MIC of different susceptible micro-
organisms responsible for serious disease problems. Consequently, a suitable intramuscular dosage
regimen for cefoperazone was 20 mg/kg repeated at 12 h intervals in goats. The drug was detected in
urine up to 12 and 18 h following i.v. and i.m. administration, respectively.
 2015 Production and hosting by Elsevier B.V. on behalf of Faculty of Veterinary Medicine, Cairo
University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Cefoperazone is a semi-synthetic third generation, piperazine
b-lactam antibiotics that possesses broad spectrum activity
against aerobic and anaerobic gram-positive and gram-
negative bacteria [1]. Cefoperazone is used in the treatment
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diarrhea and pneumonia [3] and has good penetration into the
pancreas indicating its usefulness for the prophylaxis and ther-
apy of secondary pancreatic infections [4]. Only a few cepha-
losporins have a high biliary excretion, cefoperazone being
one of them. Cefoperazone exhibits a longer half-life of elimi-
nation than older members of the group [5] and good penetra-
tion into organic bone [6]. The pharmacokinetics of
cefoperazone had been investigated in a number of animal spe-
cies including unweaned calves [7], horse [8], dog [9], buffalo
calves [10,11], cross bred calves [12,13] and sheep [14]. The
aim of the study was to determine the pharmacokinetic param-
eters of cefoperazone following a single intravenous and intra-
muscular administration at the dose of 20 mg/kgb.wt. in goats.
2. Materials and methods
2.1. Drugs and chemicals
Cefoperazone sodium powder (CEFOBID, produced by
Smithkline Beecham Egypt LLc for Pfizer Egypt) was diluted
with sterile water just prior to administration. Mueller–Hinton
agar was purchased from Mast Group Ltd., Merseyside, UK.
2.2. Animals
Ten clinically normal goats were used in this investigation. The
body weight and age ranged from 23 to 31 kg and from 2 to
3 years old, respectively. Animals were housed in hygienic
stable, fed on barseem, drawa and concentrate. Water was pro-
vided ad libitum. None of the animals were treated with antibi-
otics for one month prior to the trial.
2.2.1. Experimental design
The study was performed in two phases, following a crossover
design (2  2) with a 15-day washout period between the two
phases. Five animals were given a single i.v. injection into
the left jugular vein at a dose of 20 mg/kg body weight (b.
wt.) cefoperazone, and the other five were injected i.m. into
the gluteal muscle with the drug at the same dose. Five millili-
ter venous whole blood samples were taken. The sampling
times were 0.08, 0.166, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 18 and 24 h
after treatment. Blood samples were left to clot; the clear sera
were separated by centrifugation at 3000 r.p.m for 15 min and
stored at 20 C until assayed. After washout period of
15 days, the animals that had been injected i.v. with the drug
were injected i.m. and vice versa. Blood was collected and pro-
cessed as above. Goats were catheterized with an indwelling
balloon catheter (Foley Urinary Catheter, No. 12, Timedco,
Atlanta, GA, USA). 5 ml urine samples were collected at 0.5,
1, 2, 4, 6, 8, 12, 18, 24, 36 and 48 h after administration of
the drug. The samples stored at 20 C until assayed.
2.2.2. Drug bioassay
Concentrations of cefoperazone in samples were determined
by the microbiological assay method described by [15] using
Escherichia coli (ATCC 10536) as test organism [13]. This
method estimated the level of drug having antibacterial activ-
ity, without differentiating between the parent drug and its
active metabolites. The application of microbiological assay
for measuring cefoperazone concentration is suitable [13]. Sixwells were made at equal distances in standard petri-dishes
containing 25 ml seeded agar. The wells were filled with
100 ll of either the test samples or the cefoperazone standard
concentrations. The plates were kept at room temperature for
2 h before being incubated at 37 C for 18 h. Zones of inhibi-
tion were measured using micrometers and the cefoperazone
concentrations in the test samples were calculated from the
standard curve. Cefoperazone standard solution of concentra-
tions of 0.5–100 lg/ml were prepared in antibiotic-free goats
serum and phosphate buffer saline. Standard curves of cefop-
erazone were prepared in antibacterial-free goat serum by the
appropriate serial dilution. The standard curve in goat serum
was linear over the range from 0.5 to 100 lg/ml and the value
of correlation coefficient (r) was 0.991. The limit of quantifica-
tion was 0.5 lg/ml. Protein binding of cefoperazone was esti-
mated according to [16].
2.3. Pharmacokinetic analysis
A pharmacokinetic computer program (R-strip, Micro-math,
Scientific software, USA) was used to analyse the concentra-
tion–time curves for each individual animal after the adminis-
tration of cefoperazone by different routes. Following i.v. and
i.m. administrations, the appropriate pharmacokinetic model
was determined by visual examination of individual concentra-
tion–time curves and by application of Akaike’s information
criterion (AIC) [17]. The pharmacokinetic parameters were
reported as mean ± SE. All statistical analysis was carried
out according to [18].
3. Results
Mean serum concentrations of cefoperazone in goats following
i.v. and i.m. administrations of 20 mg/kg are summarized in
(Fig. 1). These data are best fitted to a two-compartment open
model and the drug was detected in serum up to 8 and 12 h fol-
lowing i.v. and i.m. administration, respectively. The pharma-
cokinetic parameters of cefoperazone in goats following i.v.
and i.m. administration of 20 mg/kg are summarized in
(Tables 1 and 2). Following i.v. administration, cefoperazone
has moderate distribution in the body of goats with Vdss of
0.44 ± 0.03 L/kg. Cefoperazone was rapidly eliminated
(T0.5(b): 1.97 ± 0.14 h) from the body. Following i.m. adminis-
tration, the drug was very rapidly absorbed with a short
absorption half life T0.5(ab) of 0.12 ± 0.01 h. The mean peak
serum concentration (Cmax) was 30.42 ± 3.53 lg ml
1
achieved at (Tmax) 0.58 ± 0.02 h. The systemic bioavailability
of cefoperazone in the goats after i.m. administration was
83.62%. In vitro protein binding was 20.34%. Mean urine con-
centrations of cefoperazone in goats following i.v. and i.m.
administration of 20 mg/kg are summarized in (Fig. 2).
4. Discussion
Following i.v. administration of cefoperazone in goats at a dose
of 20 mg/kg, no adverse effects or toxic manifestation was
observed. The results revealed that serum cefoperazone concen-
tration versus time decreased in a bi-exponential manner,
demonstrating the presence of distribution and elimination
phases and justifying the use of two-compartment open model.
This finding is in agreement with cefoperazone in horse [8], in
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Fig. 1 Semi-logarithmic graph depicting the time-concentrations course of cefoperazone in serum of goats (n= 10) following a single
intravenous and intramuscular administration of 20 mg/kg body weight.
Table 1 Mean (±SE) kinetic parameters of cefoperazone
(20 mg/kg) following a single intravenous injection in goats
(n= 10).
Parameter Unit Mean (±SE)
Cp lg ml1 102.31 ± 7.22
A lg ml1 54.10 ± 4.38
a h1 4.59 ± 0.31
T0.5(a) h 0.15 ± 0.002
Vc L kg1 0.20 ± 0.005
Vdarea L kg
1 0.38 ± 0.02
Vdss L kg
1 0.44 ± 0.03
Vd(B) L kg
1 0.41 ± 0.01
K12 h
1 2.59 ± 0.04
K21 h
1 2.15 ± 0.04
Kel h
1 0.75 ± 0.05
B lg ml1 48.20 ± 3.89
b h1 0.35 ± 0.005
T0.5(b) h 1.97 ± 0.14
AUC lg ml1 h1 149.63 ± 8.61
MRT h 2.15 ± 0.12
Cltot ml/min/kg 2.17 ± 0.10
Cp: Concentration at zero-time; A and B: Zero-time intercepts of
the biphasic disposition curve; a and b: Hybrid rate constants
representing the slopes of distribution and elimination phases,
respectively; K12: First-order constant for transfer from central to
peripheral compartment; K21: First-order constant for transfer
from peripheral to central compartment; Kel: Elimination rate
constant; T0.5(a): Distribution half-life; T0.5(b): Elimination half-life;
AUC(0inf): Area under serum concentration–time curve; MRT:
Mean residence time; Vc: Apparent volume of central compart-
ment; Vdarea: Apparent volume of distribution calculated by area
method; Vdss: Volume of distribution at steady state: Vd(B):
Apparent volume of distribution calculated by extrapolation
method; Cltot: Total body clearance.
Table 2 Mean (±SE) kinetic parameters of cefoperazone
(20 mg/kg) following a single intramuscular injection in goats
(n= 10).
Parameter Unit Mean (±SE)
A lg ml1 30.83 ± 4.32
Kab h
1 5.64 ± 0.41
T0.5(ab) h 0.12 ± 0.01
B lg ml1 37.32 ± 5.88
Kel h
1 0.27 ± 0.02
T0.5(el) h 2.53 ± 0.11
Cmax lg ml
1 30.42 ± 3.53
Tmax h 0.58 ± 0.02
AUC lg h ml1 125.12 ± 8.89
MRT h 3.34 ± 0.23
A: Zero-time intercept of distribution phase; Kab: First-order
absorption rate constant; T0.5(ab): Absorption half-life; B: Zero-
time intercept of elimination phase; Kel: First-order elimination rate
constant; T0.5(el): Elimination half-life; Cmax: Maximum serum
concentration; Tmax: Time to peak serum concentration;
AUC(0inf): Area under serum concentration–time curve; MRT:
Mean residence time.
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tributed with a short T0.5(a): 0.15 h. This value was close to
those reported in calves T0.5(a): 0.15 h [19] and dog T0.5(a):
0.20 h [9], shorter than those reported in sheep T0.5(a): 0.53 h
[14].
The elimination half-life and MRT were 1.97 and 2.15 h,
respectively, the results were near to those reported in cross
bred calves 2.05 and 2.28 h, respectively [12] and in dog 1.40
and 1.55 h, respectively [9], shorter than those reported in
sheep 3.80 and 3.29 h, respectively [14]. The value of Vdss
(0.44 L/kg) indicated moderate extravascular distribution ofthe drug. This value was close to those reported in sheep Vdss:
0.51 L/kg [14]. The total body clearance of cefoperazone fol-
lowing i.v. administration was 2.17 ml/min/kg. The value was
close to those reported in dog 1.96 ml/min/kg. [9], while it is
slower than 5.16 ml/min/kg reported in sheep [14], 8.16 ml/
min/kg reported in unweaned calves [7] and 11.50 ml/min/kg
reported in cross bred calves [12].
Following i.m. administration of cefoperazone in goats at a
dose of 20 mg/kg, the drug was very rapidly absorbed with a
short absorption half life T0.5(ab) of 0.12 h. This value was
shorter than those reported in dog 0.48 h [9]. The maximum
serum concentration (Cmax) of 30.42 lg ml
1 was attained at
(Tmax) 0.58 h post administration. However, lower value of
Cmax like 25.67 lg ml
1 at 0.5 h in sheep [14], 24.5 lg ml1 at
1.5 h in dog [9] and 9.76 lg ml1 at 0.75 h in cross bred calves
[13] had been reported.
The elimination half-life of cefoperazone following i.m.
administration was 2.53 h. This value was close to those
reported in unweaned calves 2.28 h [7], dog 2.24 h [9] and cross
bred calves 2.31 h [13]. While it is shorter than value reported
in sheep 3.32 h [14]. The mean residence time (MRT) was
3.34 h. This value was similar to those reported in cross bred
calves 3.62 h [13]. However it is shorter than value reported
in sheep 4.27 h [14] and dog 4.05 h [9], but longer than value
recorded in unweaned calves 2.34 h [7].
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Fig. 2 Semi-logarithmic graph depicting the time-concentrations course of cefoperazone in urine of goats (n= 10) following a single
intravenous and intramuscular administration of 20 mg/kg body weight.
24 T. Attia et al.The value of systemic bioavailability (83.62%) indicated
good absorption of cefoperazone from i.m. injection site. This
value was higher than those reported in unweaned calves
76.3% [7] and sheep 71.83% [14]. While this value was close
to those reported for cefepime in goats 86.45% [20] and ewes
86.8% [21]. High bioavailability of cefoperazone and mainte-
nance of therapeutic concentration up to 12 h after i.m. admin-
istration suggests that the drug is suitable for i.m.
administration for the treatment of systemic bacterial infec-
tions in goats. In vitro protein binding was 20.34%, compared
with 24.9% reported in cross bred calves [13].
The serum level of P0.2 lg ml1 for third generation
cephalosporin is considered adequate against most sensitive
bacteria, including Enterobacteriaceae Spp. [22]. However, a
serum concentration of 0.25–2.0 lg ml1 has been reported
as MIC90 of cephalosporin against animal pathogens [23]. In
the present study an average value of MIC (1.0 lg ml1) has
been taken into consideration. The drug was detected above
MIC in serum up to 8 and 12 h following i.v. and i.m. admin-
istration, respectively.
Cefoperazone was detected in urine at high concentrations
following i.v and i.m. administration for 12 and 18 h, respec-
tively. The detected concentrations of the drug in urine exceed
the MIC90 for all bacterial pathogens responsible for urinary
tract infections in goats. The result suggests the possibility of
using cefoperazone in treatment of such disease conditions in
goats.
5. Conclusion
A cefoperazone dose of 20 mg/kg is sufficient to maintain
serum concentration of the drug above the MIC90 when it is
administered at 8 and 12 h interval following intravenous
and intramuscular administration, respectively. Consequently,
cefoperazone can be used safely and effectively for treat the
infections in goats.
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